What is the ticker symbol for Pulmonx?

Pulmonx trades under the ticker LUNG on NASDAQ.

What sector does Pulmonx operate in?

Pulmonx is classified in the Healthcare sector (Medical - Devices industry).

How can PortView help analyze LUNG in a portfolio?

PortView shows LUNG's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Pulmonx (LUNG) Stock Analysis

NASDAQHealthcareMedical - Devices

$2.34+4.24%

1-year price historyRange $1.17 – $2.60

52-week range$2.34

$1.13$2.89

What Pulmonx does

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Key metrics

Market cap

$98.62M

P/E (TTM)

-2.01

EPS (TTM)

$-1.16

Beta

0.28

Dividend yield

0.00%

Revenue / share

$2.07

50-day avg

$1.77

200-day avg

$1.67

52-week high

$2.89

52-week low

$1.13

CEO

Glendon E. French

ETFs linked to LUNG

Broad-market and Healthcare sector ETFs an investor holding Pulmonx is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how LUNG fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze LUNG in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Pulmonx?: Pulmonx trades under the ticker LUNG on NASDAQ.
Which exchange is LUNG listed on?: LUNG is listed on NASDAQ.
What sector does Pulmonx operate in?: Pulmonx is classified in the Healthcare sector (Medical - Devices industry).
How can PortView help analyze LUNG in a portfolio?: PortView shows LUNG's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.